MedTrace Logo

5 Year Registry Study to Track Clinical Application of DecisionDx-UM Assay Results and Associated Patient Outcomes

NCT02376920 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 93

Last updated 2022-05-16

No results posted yet for this study

Summary

Uveal Melanoma is a rare cancer with approximately 3,000 cases diagnosed in the US every year. Nearly half of these experience spread of their cancer outside the eye. The DecisionDx-UM gene expression test classifies an individual's tumor as low risk (class 1) or high risk (class 2) of spreading. This study is being done to collect information about how physicians are using the DecisionDx-UM results to design individual treatment plans. It will also track outcomes or the uveal melanoma population that received DecisionDx-UM testing.

Conditions

Sponsors & Collaborators

  • Castle Biosciences Incorporated

    lead INDUSTRY

Principal Investigators

  • Robert Cook, PhD · Castle Biosciences Inc.

Eligibility

Min Age
16 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-03-31
Primary Completion
2022-04-30
Completion
2022-04-30

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02376920 on ClinicalTrials.gov